Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
| Autor: | Yutaka Susuta, Kazuhiro Ueshima, Yoshinobu Morikawa, Hiroyuki Kawata, Makoto Watanabe, Tsunenari Soeda, Shu Kasama, Sei Komatsu, Yasushi Okada, Masahiro Yamamoto, Masato Kasahara, Tomoya Nakano, Akiomi Yoshihisa, Masafumi Nakayama, Kenichi Tsujita, Rika Kawakami, Tomoya Ueda, Hiroyuki Tanaka, Yasuchika Takeishi, Yoshihiko Saito |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Urology Type 2 diabetes law.invention Sodium-glucose cotransporter 2 inhibitors Elderly Randomized controlled trial law medicine Natriuretic peptide Canagliflozin Heart Failure Ejection fraction business.industry Original article General Medicine medicine.disease Heart failure with preserved ejection fraction B-type natriuretic peptide SGLT2 Inhibitor business Body mass index medicine.drug |
| Zdroj: | Circulation Reports |
| ISSN: | 2434-0790 |
| Popis: | Background: The efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in elderly patients with heart failure with preserved ejection fraction (HFpEF) remains unclear. Methods and Results: In a multicenter, controlled trial, the CANONICAL study, we enrolled 82 HFpEF (left ventricular ejection fraction [LVEF] ≥50%) patients with type 2 diabetes (T2D) aged ≥65 years, with plasma B-type natriuretic peptide (BNP) ≥100 pg/mL or plasma N-terminal pro BNP (NT-proBNP) ≥400 pg/mL or history of HF. Patients were randomly assigned to 2 groups and were administered either the SGLT2 inhibitor canagliflozin (100 mg/day) for 24 weeks or standard therapy. The primary endpoints were changes in body weight (BW) and BNP concentrations. Mean (±SD) patient age, body mass index, and LVEF were 75.7±6.5 years, 25.0±3.6 kg/m2 and 61.5±7.6%, respectively. At 24 weeks, BW was significantly lower in the canagliflozin than standard therapy group. The extent of BNP reductions at 4 weeks was significantly greater in the canagliflozin than standard therapy group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|